Serum Institute
-
{
- All
- News
- Videos
-
Serum Institute And Oxford Partner For Bundibugyo Ebola Vaccine Clinical Trials
Supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the collaboration aims to rapidly manufacture vaccine doses and begin clinical trials.
-
Serum Institute's Cyrus Poonawalla Buys Raja Ravi Varma Painting For Record Rs 167 Crore
Managing director of the Serum Institute of India, Dr Cyrus S Poonawalla, acquired Raja Ravi Varma's iconic painting Yashoda and Krishna
-
"Not Humanly Possible To...": Adar Poonawalla On Work Hours vs Productivity
Amid the nationwide debate on work-life balance after problematic remarks by some industry leaders, Adar Poonawalla, CEO of vaccine manufacturer Serum Institute, has said it is not humanly possible to be productive beyond a certain number of hours
-
"Really Hate Mosquitoes": At Davos, Adar Poonawalla Explains Vaccine Plans To NDTV
Serum Institute of India CEO Adar Poonawalla spoke to NDTV on a range of issues, key among them the vaccine for malaria and other mosquito-borne diseases, on the sidelines of the World Economic Forum (WEF) meeting in Davos.
-
Serum Institute Says Working To Develop Monkeypox Vaccine
Serum Institute of India on Tuesday said it is currently working to develop a vaccine for Monkeypox, with positive outcomes expected in a year's time.
-
Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa
A new "high efficacy" malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M.
-
Serum Institute Begins Shipments Of Malaria Vaccine 'R21/Matrix-M' To Africa
Vaccines manufacturer Serum Institute of India (SII) on Monday said it has started exports of 'R21/Matrix-M' malaria vaccine to Africa as part of the global fight against the disease.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
Serum Institute Boosts Supply Of Cervical Cancer Shots Ahead Of Mass Drive
Serum Institute of India aims to significantly boost supply of its human papillomavirus (HPV) vaccine as it gears up to provide its shots to the government at cheaper rates for an immunisation campaign this year against the cancer-causing virus.
-
Vaccine Maker Adar Poonawalla To Buy Mansion In London's Mayfair. It Costs...
Billionaire CEO of Serum Institute of India, Adar Poonawalla, has sealed a deal to buy a multi-million-pound mansion in London's Mayfair, the Financial Times reported.
-
Oxford University, Serum Institute Deliver 'High Efficacy' Malaria Vaccine
A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday.
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
-
Serum Institute And Oxford Partner For Bundibugyo Ebola Vaccine Clinical Trials
Supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the collaboration aims to rapidly manufacture vaccine doses and begin clinical trials.
-
Serum Institute's Cyrus Poonawalla Buys Raja Ravi Varma Painting For Record Rs 167 Crore
Managing director of the Serum Institute of India, Dr Cyrus S Poonawalla, acquired Raja Ravi Varma's iconic painting Yashoda and Krishna
-
"Not Humanly Possible To...": Adar Poonawalla On Work Hours vs Productivity
Amid the nationwide debate on work-life balance after problematic remarks by some industry leaders, Adar Poonawalla, CEO of vaccine manufacturer Serum Institute, has said it is not humanly possible to be productive beyond a certain number of hours
-
"Really Hate Mosquitoes": At Davos, Adar Poonawalla Explains Vaccine Plans To NDTV
Serum Institute of India CEO Adar Poonawalla spoke to NDTV on a range of issues, key among them the vaccine for malaria and other mosquito-borne diseases, on the sidelines of the World Economic Forum (WEF) meeting in Davos.
-
Serum Institute Says Working To Develop Monkeypox Vaccine
Serum Institute of India on Tuesday said it is currently working to develop a vaccine for Monkeypox, with positive outcomes expected in a year's time.
-
Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa
A new "high efficacy" malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M.
-
Serum Institute Begins Shipments Of Malaria Vaccine 'R21/Matrix-M' To Africa
Vaccines manufacturer Serum Institute of India (SII) on Monday said it has started exports of 'R21/Matrix-M' malaria vaccine to Africa as part of the global fight against the disease.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
Serum Institute Boosts Supply Of Cervical Cancer Shots Ahead Of Mass Drive
Serum Institute of India aims to significantly boost supply of its human papillomavirus (HPV) vaccine as it gears up to provide its shots to the government at cheaper rates for an immunisation campaign this year against the cancer-causing virus.
-
Vaccine Maker Adar Poonawalla To Buy Mansion In London's Mayfair. It Costs...
Billionaire CEO of Serum Institute of India, Adar Poonawalla, has sealed a deal to buy a multi-million-pound mansion in London's Mayfair, the Financial Times reported.
-
Oxford University, Serum Institute Deliver 'High Efficacy' Malaria Vaccine
A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday.
-
Serum Institute Restarts Manufacturing Of COVID-19 Vaccine Covishield
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Restarts Production Of Covishield Vaccine After Cases Rise
Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
